Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

FreeStyle Libre 2 Sensors added to Drug Tariff and DND list  

The new FreeStyle Libre 2 Sensors recently launched by Abbott Diabetes Care Ltd have been added to the Appliances section in Part IXA of the November 2020 Drug Tariff.

The product is also included in the list of drugs for which discount is not deducted (DND).


The introduction of the second-generation FreeStyle Libre 2 Flash Glucose Monitoring system follows the launch of the original FreeStyle Libre system which saw a growth in prescribing after extra NHS funding was made available from April 2019.

“As there is no discount offered by the manufacturer for purchases of the FreeStyle Libre 2 Sensors, following representations by PSNC to avoid contractors dispensing this appliance at a loss, the Department of Health and Social Care (DHSC) agreed to its addition to the DND list,” Pharmaceutical Services Negotiating Committee (PSNC) has said.

FreeStyle Libre 2 Sensors are not interchangeable with FreeStyle Libre Sensors and require a different reader or the FreeStyle LibreLink app to scan and receive the results.

The arrangements for ordering the FreeStyle Libre 2 sensors remain the same as for the original sensors – via the Abbott Diabetes Care pharmacy ordering portal.

More For You

Astrazeneca Office Building  Outlook

British Medical Journal has found data discrepancy during the crucial clinical trials of AstraZeneca's heart drug ticagrelor.

iStock

Top medics question trials of AstraZeneca's anti-clotting pill

The effectiveness of anti-clotting pill ticagrelor is now under a cloud, with some experts claiming that AstraZeneca misreported data when the trials were conducted more than a decade ago.

Sold as Brilinta, the pill was approved for use on the NHS in 2011 after trials claimed it could prevent one in five deaths after a heart attack, and the generic versions of the drug are scheduled for this year.

Keep ReadingShow less
Boots pension dispute

The Pensions Ombudsman has begun an investigation into the decision by the Trustees of Boots Pension Scheme to remove members' option to retire on an unreduced pension at age 60.

iStock

Pensions Ombudsman probing Boots pension dispute

The Pensions Ombudsman has begun an investigation into the decision by the Trustees of Boots Pension Scheme to remove members' option to retire on an unreduced pension at age 60.

According to the Pharmacists' Defence Association (PDA), the ombudsman has decided to take a ‘lead case’ approach, as several members have been affected by the issue.

Keep ReadingShow less
23andMe

More than 150,000 UK residents had their personal information taken by hackers during a data breach in 2023.

iStock

UK watchdog fines 23andMe £2.31m for data breach

Genetic testing firm 23andMe has been fined £2.31 million by a UK watchdog over a 2023 data breach, when the personal information of seven million people across the world was stolen.

The Information Commissioner's Office (ICO) said the California-based company, which later filed for bankruptcy, failed to put adequate measures in place to secure sensitive user data.

Keep ReadingShow less
Henry Gregg, new Chief Executive of the National Pharmacy Association.
Henry Gregg
Henry Gregg

Community pharmacy voices need to be ‘heard really loud’, new NPA chief tells Pharmacy Business

Henry Gregg, the new chief executive of the National Pharmacy Association (NPA), believes community pharmacies have a right to have insight into discussions relating to the pharmacy funding contract.

Currently, Community Pharmacy England (CPE) solely negotiates the elements of the Community Pharmacy Contractual Framework (CPCF) with the Department of Health and Social Care (DHSC) and NHS England.

Keep ReadingShow less
Patient care

The NHS said the benefits were "too small to justify the additional cost"

NHS rejects Alzheimer's drugs shown to delay early-stage of disease

Two new treatments for Alzheimer's disease will not be offered on the NHS due to high costs and "too small" benefits.

Donanemab and Lecanemab have been hailed as breakthrough treatments for slowing down the symptoms of early-stage Alzheimer's, the most common type of dementia.

Keep ReadingShow less